N. Harold

发表

Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin

A. Chen, C. Takimoto, J. Grem, 2003, Cancer Chemotherapy and Pharmacology.

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

S. Steinberg, J. Trepel, W. Figg, 2016, BJU international.

Clinical significance of the FV:Q506 mutation in unselected oncology patients.

S. Steinberg, F. Kaye, G. Otterson, 1996, The American journal of medicine.

Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.

C. Takimoto, J. Grem, J. Shapiro, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of BAY 43–9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling

P. Meltzer, E. Kohn, E. Posadas, 2005 .

Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil

J. Grem, R. Wilson, D. Dougherty, 2001, Anti-cancer drugs.

Phase I a nd P harmacokinetic T rial o f W eekly O ral Fluorouracil G iven W ith E niluracil a nd Low-Dose L eucovorin t o P atients W ith S olid T umors

C. Takimoto, J. Grem, J. Shapiro, 2013 .

Phase I and Pharmacokinet ic Tria l o f Weekly Oral Fluorourac i l Given With Eni lurac i l and Low-Dose Leucovor in to Pat ients With Sol id Tumors

C. Takimoto, J. Grem, J. Shapiro, 2000 .

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients.

S. Arbuck, C. Takimoto, J. Grem, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.

Anurag K. Singh, J. Dancey, D. Citrin, 2010, International journal of radiation oncology, biology, physics.

A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors

E. Szabo, J. Grem, G. Leonard, 2005, Clinical Cancer Research.

A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer

H. Parnes, J. Trepel, W. Figg, 2015, BJU international.

A phase I study of TRC 105 anti-endoglin ( CD 105 ) antibody in metastatic castration-resistant prostate cancer

H. Parnes, J. Trepel, W. Figg, 2015 .

A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.

S. Steinberg, P. Johnston, C. Takimoto, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC).

W. J. Ramsey, C. Link, N. Vahanian, 2013 .

Correlation of interferon-g (IFN-γ) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC).

W. J. Ramsey, C. Link, N. Vahanian, 2012 .

APhase IPharmacologic and PharmacogeneticTrial of Sequential 24-Hour Infusion of Irinotecan Followedby Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with SolidTumors

E. Szabo, J. Grem, G. Leonard, 2005 .

A phase I pharmacologic and pharmacodynamic study of pyrazoloacridine given as a weekly 24-hour continuous intravenous infusion in adult cancer patients.

A. Chen, C. Takimoto, J. Grem, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule

E. Szabo, J. Grem, J. M. Hamilton, 2003, Cancer chemotherapy and pharmacology.

Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.

J. Grem, J. Shapiro, B. Schuler, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer

J. Grem, G. Leonard, B. Schuler, 2005, BMC Cancer.

A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients

A. Chen, S. Arbuck, C. Takimoto, 2001, Cancer Chemotherapy and Pharmacology.

Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

S. Steinberg, J. Trepel, J. Wright, 2015 .

Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations in metastatic castrate resistant prostate cancer (mCRPC).

H. Parnes, J. Wright, W. Figg, 2013 .

A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).

S. Steinberg, H. Parnes, J. Trepel, 2013 .

Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.

H. Parnes, J. Wright, W. Figg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

S. Steinberg, J. Trepel, J. Wright, 2014 .